Differences in affected pathways as a function of genotype
| Pathways, genotype . | Genes . | P . |
|---|---|---|
| Ingenuity pathways | ||
| G1/S checkpoint regulation | ||
| +/+ | Myc, Ccnd22, Hdac6, E2f2 | < .001 |
| +/2 | Ccnd1 | .15 |
| 2/2 | Myc | .12 |
| Leukocyte extravasation signaling | ||
| +/+ | Vav32, Vcl, Itk, Mmp14, Plcg2 | < .001 |
| +/2 | — | — |
| 2/2 | Pecam1, Itk | .071 |
| B-cell receptor signaling | ||
| +/+ | Vav32, Ets1, Plcg2 | .007 |
| +/2 | Pou2f2, Rras2, Ets1 | .01 |
| 2/2 | Raf1 | .29 |
| ERK/MAPK signaling | ||
| +/+ | Myc, Ets1, Plcg2 | .015 |
| +/2 | Rras2, Prkar2b, Mycn, Ets1 | .003 |
| 2/2 | Myc, Raf1 | .072 |
| FcϵRI signaling | ||
| +/+ | Vav32, Plcg2 | .03 |
| +/2 | Rras2 | .26 |
| 2/2 | Raf1 | .2 |
| Natural killer cell signaling | ||
| +/+ | Vav32, Plcg2 | .035 |
| +/2 | Rras2 | .28 |
| 2/2 | Raf1 | .22 |
| GM-CSF signaling | ||
| +/+ | Ets1 | .15 |
| +/2 | Rras2, Ccnd1, Ets1 | < .001 |
| 2/2 | Raf1 | .13 |
| G-protein–coupled receptor signaling | ||
| +/+ | Rasgrp1 | .42 |
| +/2 | Pde1a, Rras2, Prkar2b, Rasgrp12 | .003 |
| 2/2 | Raf1, Rasgrp1 | .076 |
| Axonal guidance signaling | ||
| +/+ | — | — |
| +/2 | Arhgef6, Rras2, Prkar2b, Rtn4 | .025 |
| 2/2 | Arhgef6, Raf1 | .21 |
| PI3K/AKT signaling | ||
| +/+ | — | — |
| +/2 | Rras2, Ccnd1 | .062 |
| 2/2 | Bcl2, Raf1 | .037 |
| PTEN signaling | ||
| +/+ | — | — |
| +/2 | Rras2, Ccnd1 | .04 |
| 2/2 | Bcl2, Raf1 | .024 |
| KEGG pathways | ||
| Dorsal-ventral axis formation | ||
| +/+ | Ets1, Notch1 | .14 |
| +/2 | Rras2, Ets1, Notch12 | .011 |
| 2/2 | Raf1 | > .5 |
| Leukocyte transendothelial migration | ||
| +/+ | Plcg2, Vav3, Vcl, Itk | .019 |
| +/2 | — | — |
| 2/2 | Pecam1, Itk | .4 |
| JAK-STAT signaling | ||
| +/+ | Myc, Il21r, Ccnd2 | .16 |
| +/2 | Ccnd1 | > .5 |
| 2/2 | Il12a, Myc, Mpl, Socs6 | .023 |
| MAPK signaling | ||
| +/+ | Myc, Mef2c, Rasgrp1 | .36 |
| +/2 | Rras2, Map3k7ip2, Evi1, Mef2c, Rasgrp1 | .047 |
| 2/2 | Myc, Mef2c, Rasgrp1, Raf1 | .097 |
| Pathways, genotype . | Genes . | P . |
|---|---|---|
| Ingenuity pathways | ||
| G1/S checkpoint regulation | ||
| +/+ | Myc, Ccnd22, Hdac6, E2f2 | < .001 |
| +/2 | Ccnd1 | .15 |
| 2/2 | Myc | .12 |
| Leukocyte extravasation signaling | ||
| +/+ | Vav32, Vcl, Itk, Mmp14, Plcg2 | < .001 |
| +/2 | — | — |
| 2/2 | Pecam1, Itk | .071 |
| B-cell receptor signaling | ||
| +/+ | Vav32, Ets1, Plcg2 | .007 |
| +/2 | Pou2f2, Rras2, Ets1 | .01 |
| 2/2 | Raf1 | .29 |
| ERK/MAPK signaling | ||
| +/+ | Myc, Ets1, Plcg2 | .015 |
| +/2 | Rras2, Prkar2b, Mycn, Ets1 | .003 |
| 2/2 | Myc, Raf1 | .072 |
| FcϵRI signaling | ||
| +/+ | Vav32, Plcg2 | .03 |
| +/2 | Rras2 | .26 |
| 2/2 | Raf1 | .2 |
| Natural killer cell signaling | ||
| +/+ | Vav32, Plcg2 | .035 |
| +/2 | Rras2 | .28 |
| 2/2 | Raf1 | .22 |
| GM-CSF signaling | ||
| +/+ | Ets1 | .15 |
| +/2 | Rras2, Ccnd1, Ets1 | < .001 |
| 2/2 | Raf1 | .13 |
| G-protein–coupled receptor signaling | ||
| +/+ | Rasgrp1 | .42 |
| +/2 | Pde1a, Rras2, Prkar2b, Rasgrp12 | .003 |
| 2/2 | Raf1, Rasgrp1 | .076 |
| Axonal guidance signaling | ||
| +/+ | — | — |
| +/2 | Arhgef6, Rras2, Prkar2b, Rtn4 | .025 |
| 2/2 | Arhgef6, Raf1 | .21 |
| PI3K/AKT signaling | ||
| +/+ | — | — |
| +/2 | Rras2, Ccnd1 | .062 |
| 2/2 | Bcl2, Raf1 | .037 |
| PTEN signaling | ||
| +/+ | — | — |
| +/2 | Rras2, Ccnd1 | .04 |
| 2/2 | Bcl2, Raf1 | .024 |
| KEGG pathways | ||
| Dorsal-ventral axis formation | ||
| +/+ | Ets1, Notch1 | .14 |
| +/2 | Rras2, Ets1, Notch12 | .011 |
| 2/2 | Raf1 | > .5 |
| Leukocyte transendothelial migration | ||
| +/+ | Plcg2, Vav3, Vcl, Itk | .019 |
| +/2 | — | — |
| 2/2 | Pecam1, Itk | .4 |
| JAK-STAT signaling | ||
| +/+ | Myc, Il21r, Ccnd2 | .16 |
| +/2 | Ccnd1 | > .5 |
| 2/2 | Il12a, Myc, Mpl, Socs6 | .023 |
| MAPK signaling | ||
| +/+ | Myc, Mef2c, Rasgrp1 | .36 |
| +/2 | Rras2, Map3k7ip2, Evi1, Mef2c, Rasgrp1 | .047 |
| 2/2 | Myc, Mef2c, Rasgrp1, Raf1 | .097 |